What is at issue?
Targeted therapies play an important role in modern cancer treatment. These therapies specifically attack cancer cells, but leave normal cells virtually unaffected and are therefore very effective and have very few side effects. As a developer and manufacturer of cancer therapies, Boehringer Ingelheim is interested in knowing more about possible “targets” and in identifying molecules that might be suitable for potential drugs. A promising field of research is the BAF complex; this is a protein complex that is mutated in cancer cells in about 20% of all human cancers, and in ovarian cancer and some forms of lung cancer this figure can go up to 80%.
The research question: How can cancer cells be identified and attacked?
The BAF complex allows sequences of DNA to be read by shifting histones, around which the DNA is wound like a spool, thereby playing a part in regulating which parts of the DNA are transcribed. It thus controls which different properties are expressed by different cells despite identical DNA, for example whether they are skin or muscle cells or how they react to environmental influences. The complex consists of 29 proteins encoded by 29 genes. In tumour cells, one of these genes is mutated. The protein is not produced, instead it is replaced by other — wrong — proteins. This is where a successful drug has to attack in order to target the mutated cells as precisely as possible. The aim is therefore to gain an in-depth understanding of the BAF complex in order to find substances that kill the mutated cells or inhibit their reproduction. Scientists are looking for small organic molecules that are readily bioavailable, which means they can reach the BAF complex in the cell nucleus when taken orally.
Cooperation in the CD Laboratory
Although the BAF complex has been known for some time, there are still many open questions. It is hoped that academic research will provide more biological knowledge and a better understanding of the molecules involved: How exactly does the BAF complex work, what factors affect it, can its function be predicted? How is gene expression regulated, which genes are active? Or more specifically: What characterises a cancer cell, how does it work?
Dr Kubicek and his team are part of the scientific community and are able to work on these questions to the required depth and at the highest scientific level. The CD Laboratory thus provides the best systematic analysis of the BAF complex.
This allows the company early access to basic research results and gives it a head start; relevant results are patented. The scientific publications by the CD Laboratory position Boehringer Ingelheim as a research-based company enabling it to expand its network in the scientific field.
The CD Laboratory provided a better understanding of the structure and the subunits of the BAF complex, to which Boehringer Ingelheim has had access one to two years earlier than its competitors. Furthermore, two target proteins have already been identified. This opens up new possibilities in the search for new active substances that have the potential to be approved as drugs in a few years' time. Boehringer Ingelheim's in-house research is based on these results.